- Home
- FEMY vs PHIO Comparison
FEMY vs PHIO Comparison
Compare FEMY & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- PHIO
- Stock Information
- Founded
- FEMY 2004
- PHIO 2011
- Country
- FEMY United States
- PHIO United States
- Employees
- FEMY N/A
- PHIO N/A
- Industry
- FEMY Medical/Dental Instruments
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- FEMY Health Care
- PHIO Health Care
- Exchange
- FEMY Nasdaq
- PHIO Nasdaq
- Market Cap
- FEMY 12.5M
- PHIO 12.1M
- IPO Year
- FEMY 2021
- PHIO N/A
- Fundamental
- Price
- FEMY $0.36
- PHIO $2.11
- Analyst Decision
- FEMY Strong Buy
- PHIO Strong Buy
- Analyst Count
- FEMY 3
- PHIO 3
- Target Price
- FEMY $7.33
- PHIO $10.67
- AVG Volume (30 Days)
- FEMY 2.9M
- PHIO 130.4K
- Earning Date
- FEMY 11-11-2025
- PHIO 11-13-2025
- Dividend Yield
- FEMY N/A
- PHIO N/A
- EPS Growth
- FEMY N/A
- PHIO N/A
- EPS
- FEMY N/A
- PHIO N/A
- Revenue
- FEMY $1,887,016.00
- PHIO N/A
- Revenue This Year
- FEMY $103.55
- PHIO N/A
- Revenue Next Year
- FEMY $148.13
- PHIO N/A
- P/E Ratio
- FEMY N/A
- PHIO N/A
- Revenue Growth
- FEMY 98.61
- PHIO N/A
- 52 Week Low
- FEMY $0.31
- PHIO $0.97
- 52 Week High
- FEMY $1.80
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- FEMY 28.31
- PHIO 46.25
- Support Level
- FEMY $0.35
- PHIO $2.06
- Resistance Level
- FEMY $0.40
- PHIO $2.57
- Average True Range (ATR)
- FEMY 0.04
- PHIO 0.14
- MACD
- FEMY 0.01
- PHIO 0.01
- Stochastic Oscillator
- FEMY 5.20
- PHIO 24.59
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.